For the past several days, shares of Sun Pharmaceutical Industries Ltd, a significant large-cap pharmaceutical company, have been trading at back-to-back 52-week highs on the BSE. Today, despite the poor market the share is trading 1.07% higher at Rs 1,750.15.
Sun Pharmaceutical Industries’ Group CFO, CS Muralidharan, told CNBC-TV18 that the firm will stick to its prior topline growth estimates and that all of its businesses are now well-positioned for growth.
For the April–June quarter, the company had US formulation sales of $466 million, a 1% decrease over the same period in the previous year. Additionally, the number is far less than the $518 million prediction.
Disclaimer: The information provided in this article is for informational purposes only and should not be considered as financial advice. The data and figures presented are based on publicly available information and may be subject to change. Before making any investment decisions, it is recommended to conduct thorough research, consult with financial advisors, and consider your individual investment goals and risk tolerance. The author and publisher of this article do not assume any responsibility for any investment decisions made based on the information provided.